The DOI matches its Crossref record; 150 of the 150 references it cites were found in a registry or an index.
Therapeutic vaccines for cancer: an overview of clinical trials
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., Redfern, C. H., Ferrari, A. C., Dreicer, R., Sims, R. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001294 · Cited by 5,572
Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., et al. (2004) · Nature Medicine · doi:10.1038/nm1093 · Cited by 5,151
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496
Nivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230
Cancer immunotherapy comes of age
Mellman, I., Coukos, G., & Dranoff, G. (2011) · Nature · doi:10.1038/nature10673 · Cited by 3,893
A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma
van der Bruggen, P., Traversari, C., Chomez, P., Lurquin, C., De Plaen, E., Van den Eynde, B., Knuth, A., & Boon, T. (1991) · Science · doi:10.1126/science.1840703 · Cited by 3,545
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
Hamid, O., Robert, C., Daud, A., Hodi, F. S., Hwu, W.-J., Kefford, R., Wolchok, J. D., Hersey, P., Joseph, R. W., Weber, J. S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305133 · Cited by 3,392
Immunogenic cell death and DAMPs in cancer therapy
Krysko, D. V., Garg, A. D., Kaczmarek, A., Krysko, O., Agostinis, P., & Vandenabeele, P. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3380 · Cited by 3,223
Apetoh, L., Ghiringhelli, F., Tesniere, A., Obeid, M., Ortiz, C., Criollo, A., Mignot, G., Maiuri, M. C., Ullrich, E., Saulnier, P., et al. (2007) · Nature Medicine · doi:10.1038/nm1622 · Cited by 3,056
McLaughlin, P., Grillo-López, A. J., Link, B. K., Levy, R., Czuczman, M. S., Williams, M. E., Heyman, M. R., Bence-Bruckler, I., White, C. A., Cabanillas, F., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.8.2825 · Cited by 2,755
IDENTIFICATION OF A NOVEL CELL TYPE IN PERIPHERAL LYMPHOID ORGANS OF MICE
Steinman, R. M., & Cohn, Z. A. (1973) · The Journal of Experimental Medicine · doi:10.1084/jem.137.5.1142 · Cited by 2,424
Blackburn, S. D., Shin, H., Haining, W. N., Zou, T., Workman, C. J., Polley, A., Betts, M. R., Freeman, G. J., Vignali, D. A. A., & Wherry, E. J. (2009) · Nature Immunology · doi:10.1038/ni.1679 · Cited by 2,062
Curran, M. A., Montalvo, W., Yagita, H., & Allison, J. P. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0915174107 · Cited by 1,874
Rosenberg, S. A., Yang, J. C., Schwartzentruber, D. J., Hwu, P., Marincola, F. M., Topalian, S. L., Restifo, N. P., Dudley, M. E., Schwarz, S. L., Spiess, P. J., et al. (1998) · Nature Medicine · doi:10.1038/nm0398-321 · Cited by 1,784
DeNardo, D. G., Brennan, D. J., Rexhepaj, E., Ruffell, B., Shiao, S. L., Madden, S. F., Gallagher, W. M., Wadhwani, N., Keil, S. D., Junaid, S. A., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8274.cd-10-0028 · Cited by 1,715
mTOR regulates memory CD8 T-cell differentiation
Araki, K., Turner, A. P., Shaffer, V. O., Gangappa, S., Keller, S. A., Bachmann, M. F., Larsen, C. P., & Ahmed, R. (2009) · Nature · doi:10.1038/nature08155 · Cited by 1,575
Simpson, T. R., Li, F., Montalvo-Ortiz, W., Sepulveda, M. A., Bergerhoff, K., Arce, F., Roddie, C., Henry, J. Y., Yagita, H., Wolchok, J. D., et al. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20130579 · Cited by 1,472
TGF-β directly targets cytotoxic T cell functions during tumor evasion of immune surveillance
Thomas, D. A., & Massagué, J. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.10.012 · Cited by 1,355
Dudley, M. E., Yang, J. C., Sherry, R., Hughes, M. S., Royal, R., Kammula, U., Robbins, P. F., Huang, J., Citrin, D. E., Leitman, S. F., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.5449 · Cited by 1,332
PD-1 and PD-1 ligands: from discovery to clinical application
Okazaki, T., & Honjo, T. (2007) · International Immunology · doi:10.1093/intimm/dxm057 · Cited by 1,310
Induction of FoxP3 and acquisition of T regulatory activity by stimulated human CD4+CD25– T cells
R.Walker, M., Kasprowicz, D. J., Gersuk, V. H., Bènard, A., Van Landeghen, M., Buckner, J. H., & Ziegler, S. F. (2003) · Journal of Clinical Investigation · doi:10.1172/jci19441 · Cited by 1,245
Vincent, J., Mignot, G., Chalmin, F., Ladoire, S., Bruchard, M., Chevriaux, A., Martin, F., Apetoh, L., Rébé, C., & Ghiringhelli, F. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3690 · Cited by 1,245
Ghiringhelli, F., Menard, C., Puig, P. E., Ladoire, S., Roux, S., Martin, F., Solary, E., Le Cesne, A., Zitvogel, L., & Chauffert, B. (2007) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-006-0225-8 · Cited by 1,241
Cancer Regression and Neurological Toxicity Following Anti-MAGE-A3 TCR Gene Therapy
Morgan, R. A., Chinnasamy, N., Abate-Daga, D., Gros, A., Robbins, P. F., Zheng, Z., Dudley, M. E., Feldman, S. A., Yang, J. C., Sherry, R. M., et al. (2013) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3182829903 · Cited by 1,148
IDENTIFICATION OF A NOVEL CELL TYPE IN PERIPHERAL LYMPHOID ORGANS OF MICE
Steinman, R. M., Lustig, D. S., & Cohn, Z. A. (1974) · The Journal of Experimental Medicine · doi:10.1084/jem.139.6.1431 · Cited by 1,050
Jongbloed, S. L., Kassianos, A. J., McDonald, K. J., Clark, G. J., Ju, X., Angel, C. E., Chen, C.-J. J., Dunbar, P. R., Wadley, R. B., Jeet, V., et al. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20092140 · Cited by 1,027
Systemic effects of local radiotherapy
Formenti, S. C., & Demaria, S. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70082-8 · Cited by 1,021
Hodi, F. S., Mihm, M. C., Soiffer, R. J., Haluska, F. G., Butler, M., Seiden, M. V., Davis, T., Henry-Spires, R., MacRae, S., Willman, A., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0830997100 · Cited by 1,006
COLEY, W. B. (1893) · The American Journal of the Medical Sciences · doi:10.1097/00000441-189305000-00001 · Cited by 995
Kantoff, P. W., Schuetz, T. J., Blumenstein, B. A., Glode, L. M., Bilhartz, D. L., Wyand, M., Manson, K., Panicali, D. L., Laus, R., Schlom, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.0597 · Cited by 982
Lugade, A. A., Moran, J. P., Gerber, S. A., Rose, R. C., Frelinger, J. G., & Lord, E. M. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.12.7516 · Cited by 966
COLEY, W. B. (1991) · PubMed · Cited by 965
gp100 Peptide Vaccine and Interleukin-2 in Patients with Advanced Melanoma
Schwartzentruber, D. J., Lawson, D. H., Richards, J. M., Conry, R. M., Miller, D. M., Treisman, J., Gailani, F., Riley, L., Conlon, K., Pockaj, B., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1012863 · Cited by 911
Exploiting the Mutanome for Tumor Vaccination
Castle, J. C., Kreiter, S., Diekmann, J., Löwer, M., van de Roemer, N., de Graaf, J., Selmi, A., Diken, M., Boegel, S., Paret, C., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3722 · Cited by 810
Self-citationWalter, S., Weinschenk, T., Stenzl, A., Zdrojowy, R., Pluzanska, A., Szczylik, C., Staehler, M., Brugger, W., Dietrich, P.-Y., Mendrzyk, R., et al. (2012) · Nature Medicine · doi:10.1038/nm.2883 · Cited by 788
Blank, C., Brown, I., Peterson, A. C., Spiotto, M., Iwai, Y., Honjo, T., & Gajewski, T. F. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3259 · Cited by 772
Duraiswamy, J., Kaluza, K. M., Freeman, G. J., & Coukos, G. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4100 · Cited by 745
Klein, G., Sjögren, H. O., Klein, E., & Hellström, K. E. (1960) · PubMed · Cited by 742
Cross-presentation of viral and self antigens by skin-derived CD103+ dendritic cells
Bedoui, S., Whitney, P. G., Waithman, J., Eidsmo, L., Wakim, L., Caminschi, I., Allan, R. S., Wojtasiak, M., Shortman, K., Carbone, F. R., et al. (2009) · Nature Immunology · doi:10.1038/ni.1724 · Cited by 715
The secret ally: immunostimulation by anticancer drugs
Galluzzi, L., Senovilla, L., Zitvogel, L., & Kroemer, G. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3626 · Cited by 670
Hou, D.-Y., Muller, A. J., Sharma, M. D., DuHadaway, J., Banerjee, T., Johnson, M., Mellor, A. L., Prendergast, G. C., & Munn, D. H. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2925 · Cited by 586
Robbins, P. F., El-Gamil, M., Li, Y. F., Kawakami, Y., Loftus, D., Appella, E., & Rosenberg, S. A. (1996) · The Journal of experimental medicine · doi:10.1084/jem.183.3.1185 · Cited by 550
Butts, C., Socinski, M. A., Mitchell, P. L., Thatcher, N., Havel, L., Krzakowski, M., Nawrocki, S., Ciuleanu, T.-E., Bosquée, L., Trigo, J. M., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70510-2 · Cited by 538
Self-citationOka, Y., Tsuboi, A., Taguchi, T., Osaki, T., Kyo, T., Nakajima, H., Elisseeva, O. A., Oji, Y., Kawakami, M., Ikegame, K., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405884101 · Cited by 531
Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial
Vermorken, J. B., Claessen, A. M., van Tinteren, H., Gall, H. E., Ezinga, R., Meijer, S., Scheper, R. J., Meijer, C. J., Bloemena, E., Ransom, J. H., et al. (1999) · The Lancet · doi:10.1016/s0140-6736(98)07186-4 · Cited by 504
Ranges, G. E., Figari, I. S., Espevik, T., & Palladino, M. A. (1987) · The Journal of experimental medicine · doi:10.1084/jem.166.4.991 · Cited by 494
Hailemichael, Y., Dai, Z., Jaffarzad, N., Ye, Y., Medina, M. A., Huang, X.-F., Dorta-Estremera, S. M., Greeley, N. R., Nitti, G., Peng, W., et al. (2013) · Nature Medicine · doi:10.1038/nm.3105 · Cited by 457
Predictive Gene Signature in MAGE-A3 Antigen-Specific Cancer Immunotherapy
Ulloa-Montoya, F., Louahed, J., Dizier, B., Gruselle, O., Spiessens, B., Lehmann, F. F., Suciu, S., Kruit, W. H. J., Eggermont, A. M. M., Vansteenkiste, J., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.3762 · Cited by 436
FOXP3+ Regulatory T Cells Affect the Development and Progression of Hepatocarcinogenesis
Kobayashi, N., Hiraoka, N., Yamagami, W., Ojima, H., Kanai, Y., Kosuge, T., Nakajima, A., & Hirohashi, S. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2363 · Cited by 431
Disis, M. L., Gooley, T. A., Rinn, K., Davis, D., Piepkorn, M., Cheever, M. A., Knutson, K. L., & Schiffman, K. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.06.171 · Cited by 423
Hurwitz, A. A., Yu, T. F.-Y., Leach, D. R., & Allison, J. P. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.17.10067 · Cited by 378
Van Tendeloo, V. F., Van de Velde, A., Van Driessche, A., Cools, N., Anguille, S., Ladell, K., Gostick, E., Vermeulen, K., Pieters, K., Nijs, G., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1008051107 · Cited by 377
IMMUNOLOGICAL ASPECTS OF MALIGNANT DISEASE
Burnet, F. M. (1967) · The Lancet · doi:10.1016/s0140-6736(67)92837-1 · Cited by 369
Cancer immunoediting: antigens, mechanisms, and implications to cancer immunotherapy
Vesely, M. D., & Schreiber, R. D. (2013) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12105 · Cited by 367
Nemunaitis, J., Dillman, R. O., Schwarzenberger, P. O., Senzer, N., Cunningham, C., Cutler, J., Tong, A., Kumar, P., Pappen, B., Hamilton, C., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.5335 · Cited by 367
van den Eertwegh, A. J., Versluis, J., van den Berg, H. P., Santegoets, S. J., van Moorselaar, R. J. A., van der Sluis, T. M., Gall, H. E., Harding, T. C., Jooss, K., Lowy, I., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70007-4 · Cited by 357
Self-citationLiu, W. M., Fowler, D. W., Smith, P., & Dalgleish, A. G. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605465 · Cited by 356
Vansteenkiste, J., Zielinski, M., Linder, A., Dahabreh, J., Gonzalez, E. E., Malinowski, W., Lopez-Brea, M., Vanakesa, T., Jassem, J., Kalofonos, H., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.7103 · Cited by 318
Iclozan, C., Antonia, S., Chiappori, A., Chen, D.-T., & Gabrilovich, D. (2013) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-013-1396-8 · Cited by 317
Current Status and Future Prospects
Wood, C., Baker, G., & Trounson, A. (1984) · Clinical In Vitro Fertilization · doi:10.1007/978-1-4471-3317-9_2 · Cited by 300
Keilholz, U., Letsch, A., Busse, A., Asemissen, A. M., Bauer, S., Blau, I. W., Hofmann, W.-K., Uharek, L., Thiel, E., & Scheibenbogen, C. (2009) · Blood · doi:10.1182/blood-2009-02-202598 · Cited by 300
Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients
Parmiani, G., Castelli, C., Pilla, L., Santinami, M., Colombo, M. P., & Rivoltini, L. (2007) · Annals of Oncology · doi:10.1093/annonc/mdl158 · Cited by 300
Self-citationSlingluff, C. L. (2011) · The Cancer Journal · doi:10.1097/ppo.0b013e318233e5b2 · Cited by 299
What are regulatory T cells (Treg) regulating in cancer and why?
Whiteside, T. L. (2012) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2012.03.004 · Cited by 291
Grun, J. L., & Maurer, P. H. (1989) · Cellular Immunology · doi:10.1016/0008-8749(89)90011-7 · Cited by 281
Gjertsen, M. K., Buanes, T., Rosseland, A. R., Bakka, A., Gladhaug, I., S�reide, O., Eriksen, J. A., M�ller, M., Baksaas, I., Lothe, R. A., et al. (2001) · International Journal of Cancer · doi:10.1002/ijc.1205 · Cited by 276
Self-citationQuoix, E., Ramlau, R., Westeel, V., Papai, Z., Madroszyk, A., Riviere, A., Koralewski, P., Breton, J.-L., Stoelben, E., Braun, D., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70259-5 · Cited by 269
Miles, D., Roché, H., Martin, M., Perren, T. J., Cameron, D. A., Glaspy, J., Dodwell, D., Parker, J., Mayordomo, J., Tres, A., et al. (2011) · The Oncologist · doi:10.1634/theoncologist.2010-0307 · Cited by 262
Burch, P. A., Breen, J. K., Buckner, J. C., Gastineau, D. A., Kaur, J. A., Laus, R., Padley, D. J., Peshwa, M. V., Pitot, H. C., Richardson, R. L., et al. (2000) · PubMed · Cited by 260
Testori, A., Richards, J., Whitman, E., Mann, G. B., Lutzky, J., Camacho, L., Parmiani, G., Tosti, G., Kirkwood, J. M., Hoos, A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.9941 · Cited by 257
Self-citationButterfield, L. H., Ribas, A., Dissette, V. B., Amarnani, S. N., Vu, H. T., Oseguera, D. K., Wang, H.-J., Elashoff, R. M., McBride, W. H., Mukherji, B., et al. (2003) · PubMed · Cited by 255
Trial watch: Dendritic cell-based interventions for cancer therapy
Vacchelli, E., Vitale, I., Eggermont, A., Fridman, W. H., Fučíková, J., Cremer, I., Galon, J., Tartour, E., Zitvogel, L., Kroemer, G., et al. (2013) · OncoImmunology · doi:10.4161/onci.25771 · Cited by 247
Schuster, S. J., Neelapu, S. S., Gause, B. L., Janik, J. E., Muggia, F. M., Gockerman, J. P., Winter, J. N., Flowers, C. R., Nikcevich, D. A., Sotomayor, E. M., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.3005 · Cited by 245
Jordan, J. T., Sun, W., Hussain, S. F., DeAngulo, G., Prabhu, S. S., & Heimberger, A. B. (2008) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-007-0336-x · Cited by 243
Schellhammer, P. F., Chodak, G., Whitmore, J. B., Sims, R., Frohlich, M. W., & Kantoff, P. W. (2013) · Urology · doi:10.1016/j.urology.2013.01.061 · Cited by 242
Sandoval, F., Terme, M., Nizard, M., Badoual, C., Bureau, M.-F., Freyburger, L., Clement, O., Marcheteau, E., Gey, A., Fraisse, G., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3004888 · Cited by 238
Small, E. J., Sacks, N., Nemunaitis, J., Urba, W. J., Dula, E., Centeno, A. S., Nelson, W. G., Ando, D., Howard, C., Borellini, F., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2937 · Cited by 235
Scholl, S. M., Pallud, C., Beuvon, F., Hacene, K., Stanley, E. R., Rohrschneider, L., Tang, R., Pouillart, P., & Lidereau, R. (1994) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/86.2.120 · Cited by 226
Self-citationSuzuki, Y., Mimura, K., Yoshimoto, Y., Watanabe, M., Ohkubo, Y., Izawa, S., Murata, K., Fujii, H., Nakano, T., & Kono, K. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0851 · Cited by 219
Adotevi, O., Pere, H., Ravel, P., Haicheur, N., Badoual, C., Merillon, N., Medioni, J., Peyrard, S., Roncelin, S., Verkarre, V., et al. (2010) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181f4c208 · Cited by 213
Correale, P., Rotundo, M. S., Del Vecchio, M. T., Remondo, C., Migali, C., Ginanneschi, C., Tsang, K. Y., Licchetta, A., Mannucci, S., Loiacono, L., et al. (2010) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181d32f01 · Cited by 210
Higano, C. S., Corman, J. M., Smith, D. C., Centeno, A. S., Steidle, C. P., Gittleman, M., Simons, J. W., Sacks, N., Aimi, J., & Small, E. J. (2008) · Cancer · doi:10.1002/cncr.23669 · Cited by 210
Hardacre, J. M., Mulcahy, M., Small, W., Talamonti, M., Obel, J., Krishnamurthi, S., Rocha-Lima, C. S., Safran, H., Lenz, H.-J., & Chiorean, E. G. (2013) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-012-2064-6 · Cited by 208
Odunsi, K., Matsuzaki, J., Karbach, J., Neumann, A., Mhawech-Fauceglia, P., Miller, A., Beck, A., Morrison, C. D., Ritter, G., Godoy, H., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1117208109 · Cited by 200
Vinageras, E. N., de la Torre, A., Rodríguez, M. O., Ferrer, M. C., Bravo, I., del Pino, M. M., Abreu, D. A., Brooks, S. A., Rives, R., del Castillo Carrillo, C., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.5980 · Cited by 199
Wedén, S., Klemp, M., Gladhaug, I. P., Møller, M., Eriksen, J. A., Gaudernack, G., & Buanes, T. (2011) · International Journal of Cancer · doi:10.1002/ijc.25449 · Cited by 183
Self-citationMorton, D. L., Mozzillo, N., Thompson, J. F., Kelley, M. C., Faries, M., Wagner, J., Schneebaum, S., Schuchter, L., Gammon, G., & Elashoff, R. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.8508 · Cited by 177
Antigen Spreading Contributes to MAGE Vaccination-Induced Regression of Melanoma Metastases
Corbière, V., Chapiro, J., Stroobant, V., Ma, W., Lurquin, C., Lethé, B., van Baren, N., Van den Eynde, B. J., Boon, T., & Coulie, P. G. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2693 · Cited by 175
Aarntzen, E. H. J. G., De Vries, I. J. M., Lesterhuis, W. J., Schuurhuis, D., Jacobs, J. F. M., Bol, K., Schreibelt, G., Mus, R., De Wilt, J. H. W., Haanen, J. B. A. G., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-1127 · Cited by 174
Trial watch: Dendritic cell-based interventions for cancer therapy
Galluzzi, L., Senovilla, L., Vacchelli, E., Eggermont, A. M. M., Fridman, W. H., Galon, J., Sautès‐Fridman, C., Tartour, É., Zitvogel, L., & Kroemer, G. (2012) · OncoImmunology · doi:10.4161/onci.21494 · Cited by 173
Mittendorf, E. A., Clifton, G. T., Holmes, J. P., Clive, K. S., Patil, R., Benavides, L. C., Gates, J. D., Sears, A. K., Stojadinovic, A., Ponniah, S., et al. (2012) · Cancer · doi:10.1002/cncr.26574 · Cited by 172
Cerullo, V., Diaconu, I., Kangasniemi, L., Rajecki, M., Escutenaire, S., Koski, A., Romano, V., Rouvinen, N., Tuuminen, T., Laasonen, L., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2011.113 · Cited by 159
Brunsvig, P. F., Kyte, J. A., Kersten, C., Sundstrøm, S., Møller, M., Nyakas, M., Hansen, G. L., Gaudernack, G., & Aamdal, S. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1385 · Cited by 159
Self-citationBergmann, C., Strauss, L., Wang, Y., Szczepański, M. J., Lang, S., Johnson, J. T., & Whiteside, T. L. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-5126 · Cited by 159
Clinical Benefit Associated With Idiotypic Vaccination in Patients With Follicular Lymphoma
Inogés, S., Rodrı́guez-Calvillo, M., Zabalegui, N., de Cerio, A. L.-D., Villanueva, H., Soria, E., Suárez, L., Rodríguez‐Caballero, A., Pastor, F., García‐Muñoz, R., et al. (2006) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djj358 · Cited by 150
Self-citationMorse, M. A., Niedzwiecki, D., Marshall, J. L., Garrett, C. H., Chang, D. Z., Aklilu, M., Crocenzi, T. S., Cole, D. J., Dessureault, S., Hobeika, A. C., et al. (2013) · Annals of Surgery · doi:10.1097/sla.0b013e318292919e · Cited by 150
Hanna, M. G., Hoover, H. C., Vermorken, J. B., Harris, J. E., & Pinedo, H. M. (2001) · Vaccine · doi:10.1016/s0264-410x(00)00485-0 · Cited by 141
The Tumor-Immune Microenvironment and Response to Radiation Therapy
Shiao, S. L., & Coussens, L. M. (2010) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1007/s10911-010-9194-9 · Cited by 138
Finkelstein, S. E., Iclozan, C., Bui, M. M., Cotter, M. J., Ramakrishnan, R., Ahmed, J., Noyes, D. R., Cheong, D., González, R., Heysek, R. V., et al. (2011) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2010.12.068 · Cited by 124
Becker, J. T., Olson, B. M., Johnson, L. E., Davies, J. G., Dunphy, E. J., & McNeel, D. G. (2010) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181dda23e · Cited by 120
Salem, M. L., Diaz-Montero, C. M., Al-Khami, A. A., El-Naggar, S. A., Naga, O. S., Montero, A. J., Khafagy, A., & Cole, D. J. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0801829 · Cited by 115
Zeng, G., Li, Y., El‐Gamil, M., Sidney, J., Sette, A., Wang, R. F., Rosenberg, S. A., & Robbins, P. F. (2002) · PubMed · Cited by 114
Feyerabend, S., Stevanović, S., Gouttefangeas, C., Wernet, D., Hennenlotter, J., Bedke, J., Dietz, K., Pascolo, S., Kuczyk, M. A., Rammensee, H., et al. (2009) · The Prostate · doi:10.1002/pros.20941 · Cited by 107
Dendritic cell-based vaccination in metastatic melanoma patients: Phase II clinical trial
Oshita, C., Takikawa, M., KUME, A., Miyata, H., Ashizawa, T., Iizuka, A., Kiyohara, Y., Yoshikawa, S., Tanosaki, R., Yamazaki, N., et al. (2012) · Oncology Reports · doi:10.3892/or.2012.1956 · Cited by 106
Potential of CXCR4 antagonists for the treatment of metastatic lung cancer
Burger, J. A., Stewart, D. J., Wald, O., & Peled, A. (2011) · Expert Review of Anticancer Therapy · doi:10.1586/era.11.11 · Cited by 106
Morse, M. A., Chaudhry, A., Gabitzsch, E. S., Hobeika, A. C., Osada, T., Clay, T. M., Amalfitano, A., Burnett, B. K., Devi, G. R., Hsu, D. S., et al. (2013) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-013-1400-3 · Cited by 98
Dillman, R. O., Cornforth, A. N., DePriest, C. B., McClay, E. F., AMATRUDA, T. T., de Leon, C., Ellis, R. A., Mayorga, C., Carbonell, D. J., & Cubellis, J. M. (2012) · Journal of Immunotherapy · doi:10.1097/cji.0b013e31826f79c8 · Cited by 95
Yuan, J. D., Ginsberg, B., Page, D. B., Li, Y., Rasalan, T. S., Gallardo, H. F., Xu, Y., Adams, S., Bhardwaj, N., BUSAM, K. J., et al. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-1011-9 · Cited by 95
Ibrahim, N. K., Murray, J. L., Zhou, D., Mittendorf, E. A., Sample, D., Tautchin, M., & Miles, D. W. (2013) · Journal of Cancer · doi:10.7150/jca.7028 · Cited by 93
Takeda, K., Kojima, Y., Uno, T., Hayakawa, Y., Teng, M. W. L., Yoshizawa, H., Yagita∥, H., Gejyo, F., Okumura, K., & Smyth, M. J. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903033 · Cited by 89
Wu, Y.-L. L. C., Park, K., Soo, R. A., Sun, Y. K., Tyroller, K., Wages, D. S., Ely, G., Yang, J. C., & Mok, T. S. K. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-430 · Cited by 89
Cancer Vaccines: Preclinical Studies and Novel Strategies
Palena, C., Abrams, S. I., Schlom, J., & Hodge, J. W. (2006) · Advances in cancer research · doi:10.1016/s0065-230x(06)95004-0 · Cited by 85
Desirable cell death during anticancer chemotherapy
Locher, C., Conforti, R., Aymeric, L., Ma, Y., Yamazaki, T., Rusakiewicz, S., Tesnière, A., Ghiringhelli, F., Apétoh, L., Morel, Y., et al. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2010.05763.x · Cited by 84
Potentiation of a p53‐SLP vaccine by cyclophosphamide in ovarian cancer: A single‐arm phase II study
Vermeij, R., Leffers, N., Hoogeboom, B., Hamming, I. L. E., Wolf, R., Reyners, A. K. L., Molmans, B. H. W., Hollema, H., Bart, J., Drijfhout, J. W., et al. (2012) · International Journal of Cancer · doi:10.1002/ijc.27388 · Cited by 84
Tumoricidal activity of human dendritic cells
Tel, J., Anguille, S., Waterborg, C. E. J., Smits, E., Figdor, C. G., & de Vries, I. J. M. (2013) · Trends in Immunology · doi:10.1016/j.it.2013.10.007 · Cited by 82
Becker, J. C., Andersen, M. H., Hofmeister, V., Wobser, M., Frey, L., Sandig, C., Walter, S., Singh‐Jasuja, H., Kämpgen, E., Opitz, A., et al. (2012) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-012-1266-9 · Cited by 80
Ovarian cancer cytoreduction induces changes in T cell population subsets reducing immunosuppression
Napoletano, C., Bellati, F., Landi, R., Pauselli, S., Marchetti, C., Visconti, V. V., Sale, P., Liberati, M., Rughetti, A., Frati, L., et al. (2009) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2009.00911.x · Cited by 76
Näslund, T. I., Uyttenhove, C., Nordström, E. K. L., Colau, D., Warnier, G., Jondal, M., den Eynde, B. J. V., & Liljeström, P. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.11.6761 · Cited by 74
Brahmer, J. R., Horn, L., Antonia, S. J., Spigel, D. R., Gandhi, L., Sequist, L. V. D., Sankar, V., Ahlers, C. M., Wigginton, J. M., Kollia, G. D., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.8030 · Cited by 74
Targeting AKT Signaling Sensitizes Cancer to Cellular Immunotherapy
Hähnel, P. S., Thaler, S., Antunes, E., Huber, C., Theobald, M., & Schüler, M. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6286 · Cited by 73
Self-citationGarrison, K., Hahn, T., Lee, W., Ling, L. E., Weinberg, A. D., & Akporiaye, E. T. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-1119-y · Cited by 70
Colorectal cancer immunotherapy.
Xiang, B., Snook, A. E., Magee, M. S., & Waldman, S. A. (2013) · PubMed · Cited by 65
Tarhini, A. A., Leng, S., Moschos, S. J., Yin, Y., Sander, C., Lin, Y., Gooding, W. E., & Kirkwood, J. M. (2012) · Journal of Immunotherapy · doi:10.1097/cji.0b013e31825481fe · Cited by 64
A methodological framework to enhance the clinical success of cancer immunotherapy
Hoos, A., Britten, C. M., Huber, C., & O’Donnell-Tormey, J. (2011) · Nature Biotechnology · doi:10.1038/nbt.2000 · Cited by 60
Self-citationAkiyama (2011) · International Journal of Oncology · doi:10.3892/ijo.2011.957 · Cited by 54
Abscopal but desirable: The contribution of immune responses to the efficacy of radiotherapy
Kroemer, G., & Zitvogel, L. (2012) · OncoImmunology · doi:10.4161/onci.20074 · Cited by 53
Clinical Results of Vaccine Therapy for Cancer: Learning from History for Improving the Future
Choudhury, A., Mosolits, S., Kokhaei, P., Hansson, L., Palma, M., & Mellstedt, H. (2006) · Advances in cancer research · doi:10.1016/s0065-230x(06)95005-2 · Cited by 50
Self-citationProstate cancer vaccines: Update on clinical development
Geary, S. M., & Salem, A. K. (2013) · OncoImmunology · doi:10.4161/onci.24523 · Cited by 46
Delivery of immunostimulatory monoclonal antibodies by encapsulated hybridoma cells
Dubrot, J., Portero, A., Orive, G., Hernández, R. M., Palazón, A., Rouzaut, A., Perez‐Gracia, J. L., Hervás‐Stubbs, S., Pedraz, J. L., & Melero, I. (2010) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-010-0888-z · Cited by 45
Self-citationScholl, S., Squiban, P. J., Bizouarne, N., Baudin, M., Acres, B., von Mensdorff‐Pouilly, S., Shearer, M., Beuzeboc, P., Belle, S. V., Uziely, B., et al. (2003) · BioMed Research International · doi:10.1155/s111072430320704x · Cited by 44
Self-citationCSF1 Expression in Nongynecological Leiomyosarcoma Is Associated with Increased Tumor Angiogenesis
Espinosa, Í., Edris, B., Lee, C., Cheng, H. W., Gilks, C. B., Wang, Y. Z., Montgomery, K. D., Varma, S., Li, R., Marinelli, R. J., et al. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2011.06.021 · Cited by 40
Immunological monitoring of anticancer vaccines in clinical trials
Ogi, C., & Aruga, A. (2013) · OncoImmunology · doi:10.4161/onci.26012 · Cited by 40
FMS Kinase Inhibitors: Current Status and Future Prospects
El-Gamal, M. I., Anbar, H. S., Yoo, K. H., & Oh, C. (2012) · Medicinal Research Reviews · doi:10.1002/med.21258 · Cited by 37
Is colony‐stimulating factor‐1 a key mediator of breast cancer invasion and metastasis?
Balmain, A., Barrett, J. C., Moses, H. L., Scholl, S., Crocker, P. R., Tang, R., Pouillart, P., & Pollard, J. W. (1993) · Molecular Carcinogenesis · doi:10.1002/mc.2940070402 · Cited by 34
Self-citationCytokine changes in response to radio-/chemotherapeutic treatment in head and neck cancer.
Reers, S., Pfannerstill, A.-C., Rades, D., Maushagen, R., Andratschke, M., Pries, R., & Wollenberg, B. (2013) · PubMed · Cited by 33
Ishizaki, H., Song, G.-Y., Srivastava, T., Carroll, K. D., Shahabi, V., Manuel, E. R., Diamond, D. J., & Ellenhorn, J. D. I. (2010) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181e032c6 · Cited by 32
Kübler, H. R., Maurer, T., Stenzl, A., Feyerabend, S., Steiner, U., Schostak, M., Schultze‐Seemann, W., Dorp, F. V., Pilla, L., Viatali, G., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.4535 · Cited by 31
Cancer vaccines: should we be targeting patients with less aggressive disease?
Hale, D. F., Clifton, G. T., Sears, A. K., Vreeland, T. J., Shumway, N. M., Peoples, G. E., & Mittendorf, E. A. (2012) · Expert Review of Vaccines · doi:10.1586/erv.12.39 · Cited by 30
Hallermalm, K., Johansson, S. E., Bråve, A., Ek, M., Engström, G., Boberg, A., Gudmundsdotter, L., Blomberg, P., Mellstedt, H., Stout, R., et al. (2007) · Scandinavian Journal of Immunology · doi:10.1111/j.1365-3083.2007.01945.x · Cited by 26
Self-citationAmin, A., Dudek, A. Z., Logan, T. F., Lance, R. S., Holzbeierlein, J. M., Master, V. A., Pal, S. K., Knox, J. J., Karsh, L. I., Plessinger, D., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.6_suppl.357 · Cited by 25
Baron, C. L., Raposo, G., Scholl, S., Bausinger, H., Tenza, D., Bohbot, A., Pouillart, P., Goud, B., Hanau, D., & Salamero, J. (2001) · Journal of Cell Science · doi:10.1242/jcs.114.5.999 · Cited by 22
Self-citationEnhancing adoptive immunotherapy of cancer
Westwood, J. A., Berry, L. J., Wang, L. X., Duong, C. P. M., Pegram, H. J., Darcy, P. K., & Kershaw, M. H. (2010) · Expert Opinion on Biological Therapy · doi:10.1517/14712591003610622 · Cited by 21
Middleton, G., Valle, J. W., Wadsley, J., PROPPER, D. J., Coxon, F. Y., Ross, P. J., Madhusudan, S., Roques, T. W., Cunningham, D., Corrie, P., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.lba4004 · Cited by 19
Middleton, G., Valle, J. W., Wadsley, J., PROPPER, D. J., Coxon, F. Y., Ross, P. J., Madhusudan, S., Roques, T. W., Cunningham, D., Corrie, P., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.18_suppl.lba4004 · Cited by 18
Chemotherapy ± Cetuximab Modulates Peripheral Immune Responses in Metastatic Colorectal Cancer
Xynos, I. D., Karadima, M. L., Voutsas, I. F., Amptoulach, S., Skopelitis, E. E., Kosmas, C., Gritzapis, A. D., & Tsavaris, N. B. (2013) · Oncology · doi:10.1159/000343282 · Cited by 13
The anti-tumor immune response induced by a combination of MAGE-3/MAGE-n-derived peptides
Zhang, X., Zhang, Y., Huang, Y., Qu, P., Ma, B., Si, S., Li, Z., Li, W.-X., Li, X., Ge, W., et al. (2008) · Oncology Reports · doi:10.3892/or.20.1.245 · Cited by 11
Cited by
Elements of cancer immunity and the cancer–immune set point
Chen, D. S., & Mellman, I. (2017) · Nature · doi:10.1038/nature21349 · Cited by 5,352
Dendritic cells in cancer immunology and immunotherapy
Wculek, S. K., Cueto, F. J., Mujal, A. M., Melero, I., Krummel, M. F., & Sancho, D. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0210-z · Cited by 2,574
Self-citationImmune checkpoint targeting in cancer therapy: toward combination strategies with curative potential
Sharma, P., & Allison, J. P. (2015) · Cell · doi:10.1016/j.cell.2015.03.030 · Cited by 2,345
A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization
Sanmamed, M. F., & Chen, L. (2018) · Cell · doi:10.1016/j.cell.2018.09.035 · Cited by 1,392
Combination cancer immunotherapy and new immunomodulatory targets
Mahoney, K. M., Rennert, P. D., & Freeman, G. J. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4591 · Cited by 1,294
Metadata
- Authors
- Melero, I., Gaudernack, G., Gerritsen, W., Huber, C., Parmiani, G., Scholl, S., Thatcher, N., Wagstaff, J., Zielinski, C., Faulkner, I., & Mellstedt, H.
- Venue
- Nature Reviews Clinical Oncology
- Published
- 2014-07-08
- Volume
- 11
- Issue
- 9
- Pages
- 509-524
- ISSN
- 1759-4774 (ISSN-L)
- 1759-4782
- OpenAlex
- W2137158234
- Cited by
- 776
- References
- 150
- FWCI
- 4.61
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.